Confirmed six-month disability progression rates over 4 years were similar in patients given the oral statin or a placebo in ...

Results of a world-first phase 3 trial for secondary progressive multiple sclerosis (MS), led by UCL researchers, have shown ...

Results of a world-first phase 3 trial for secondary progressive multiple sclerosis (MS), led by UCL researchers, have shown ...

Scientists compared high-intensity statins rosuvastatin and atorvastatin, and found both are broadly safe and effective at ...

The seven-year MS-STAT study, which involved almost 1,000 patients over 31 sites across the UK, concluded that simvastatin is ...

Navigating the complex world of prescription drug pricing can feel overwhelming, particularly with the ever-increasing costs ...

Atherosclerosis is the build-up of plaque in the arteries which causes their narrowing. It is a primary cause of ischemic ...

A common drug taken by millions of people in the UK has been linked to an increased risk of diabetes. Statins are taken for a ...

A group at NUS Yong Loo Lin School of Medicine (NUS Medicine) has created a nanoparticle technology that provides an efficient and non-invasive way to identify and treat atherosclerosis, according to ...

NUS Medicine researchers unveil breakthrough nanoparticle technology for atherosclerosis diagnosis and treatment Singapore ...

Pitavastatin is a novel statin that induces plaque regression and is non-inferior to atorvastatin and, on some measures, superior to simvastatin and to pravastatin in the elderly. Pitavastatin ...